Advanz Agrees Cut-Price Deal For Troubled Correvio Pharma
Firm Also Signs Agreement For UCB Portfolio
With a clear plan to move on niche and differentiated generics, complex specialty and value-added medicines, Advanz Pharma has agreed to buy debt-ridden Correvio Pharma and the rights to a portfolio from UCB, at the same time as shareholders opted to move to delist the company’s shares.
You may also be interested in...
In a move expected to unlock operational and cost efficiencies, Advanz Pharma is moving its legal and tax domicile to Jersey, close to its strategic focus on western European markets.
Korean firm Celltrion is aiming to move production of insulin pens inside Korea “for the first time” and break the stranglehold of Big Pharma insulin players in the market by launching a biosimilar product in 2025.
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.